PTC Therapeutics (NASDAQ:PTCT – Get Free Report) and CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.
Profitability
This table compares PTC Therapeutics and CollPlant Biotechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PTC Therapeutics | -9.17% | N/A | -0.10% |
| CollPlant Biotechnologies | -678.37% | -298.21% | -167.83% |
Institutional and Insider Ownership
21.7% of CollPlant Biotechnologies shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares PTC Therapeutics and CollPlant Biotechnologies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PTC Therapeutics | $1.73 billion | 3.16 | $682.64 million | ($1.40) | -46.74 |
| CollPlant Biotechnologies | $2.37 million | 3.17 | -$11.49 million | ($13.59) | -0.29 |
PTC Therapeutics has higher revenue and earnings than CollPlant Biotechnologies. PTC Therapeutics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
PTC Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for PTC Therapeutics and CollPlant Biotechnologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PTC Therapeutics | 1 | 3 | 10 | 1 | 2.73 |
| CollPlant Biotechnologies | 1 | 1 | 0 | 0 | 1.50 |
PTC Therapeutics currently has a consensus target price of $99.23, indicating a potential upside of 51.64%. CollPlant Biotechnologies has a consensus target price of $120.00, indicating a potential upside of 2,922.67%. Given CollPlant Biotechnologies’ higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than PTC Therapeutics.
Summary
PTC Therapeutics beats CollPlant Biotechnologies on 9 of the 15 factors compared between the two stocks.
About PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
